Karyopharm Therapeutics (KPTI) Q2 2024 earnings summary

Executive summary

• Total Q2 2024 revenue reached $42.8M, up from $37.6M in Q2 2023, driven by license and milestone revenue growth and supported by updated clinical data for selinexor in myelofibrosis, endometrial cancer, and multiple myeloma.

• Net income for Q2 2024 was $23.8M, reversing a net loss of $32.6M in Q2 2023, aided by a $44.7M non-cash gain on debt extinguishment and refinancing gains.

• Major refinancing in May 2024 included a $100M senior term loan, exchange of $148M in 2025 notes for $111M in 2029 notes, and issuance of 45.8M warrants, extending most debt maturities to 2028–2029.

• Global commercial presence with approvals in over 40 countries and ongoing international expansion, including new reimbursement approvals in the UK, South Korea, China, and other markets.

• Strong clinical and preclinical data support selinexor's late-stage pipeline, with key pivotal trial readouts anticipated in multiple myeloma (H1 2025), myelofibrosis (H2 2025), and endometrial cancer (early 2026).

Financial highlights

• Q2 2024 total revenue was $42.8M, with net product revenue at $28.0M and license/other revenue at $14.8M; net income was $23.8M, compared to a net loss of $32.6M in Q2 2023.

• R&D expenses rose to $38.4M, SG&A expenses decreased to $31.1M, and cost of sales was $1.5M in Q2 2024.

• Cash, cash equivalents, and investments totaled $152.5M as of June 30, 2024.

• Interest expense increased to $8.9M in Q2 2024 due to new term loan and convertible notes.

• Weighted-average shares outstanding for Q2 2024: 121.0M basic, 154.4M diluted.

Outlook and guidance

• 2024 total revenue guidance raised to $145M–$160M; U.S. XPOVIO net product revenue guidance increased to $105M–$120M.

• R&D and SG&A expense guidance lowered to $250M–$265M for 2024.

• Cash runway expected into early 2026, excluding repayment of $24.5M convertible notes due 2025 and $25M minimum liquidity covenant.

• Product revenue expected to slightly increase in the second half of 2024; license and other revenue anticipated to decrease slightly.

• Key pivotal trial data readouts expected in multiple myeloma (H1 2025), myelofibrosis (H2 2025), and endometrial cancer (early 2026).